IL269853A - Proteins for the treatment of epithelial barrier activity disorders - Google Patents

Proteins for the treatment of epithelial barrier activity disorders

Info

Publication number
IL269853A
IL269853A IL26985319A IL26985319A IL269853A IL 269853 A IL269853 A IL 269853A IL 26985319 A IL26985319 A IL 26985319A IL 26985319 A IL26985319 A IL 26985319A IL 269853 A IL269853 A IL 269853A
Authority
IL
Israel
Prior art keywords
proteins
treatment
barrier function
epithelial barrier
function disorders
Prior art date
Application number
IL26985319A
Other languages
English (en)
Hebrew (he)
Original Assignee
Second Genome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Second Genome Inc filed Critical Second Genome Inc
Publication of IL269853A publication Critical patent/IL269853A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2/00Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Prostheses (AREA)
IL26985319A 2017-04-07 2019-10-06 Proteins for the treatment of epithelial barrier activity disorders IL269853A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762482963P 2017-04-07 2017-04-07
US201762607706P 2017-12-19 2017-12-19
US201762611334P 2017-12-28 2017-12-28
PCT/US2018/026447 WO2018187682A1 (en) 2017-04-07 2018-04-06 Proteins for the treatment of epithelial barrier function disorders

Publications (1)

Publication Number Publication Date
IL269853A true IL269853A (en) 2019-11-28

Family

ID=63710147

Family Applications (1)

Application Number Title Priority Date Filing Date
IL26985319A IL269853A (en) 2017-04-07 2019-10-06 Proteins for the treatment of epithelial barrier activity disorders

Country Status (12)

Country Link
US (3) US10251933B2 (https=)
EP (1) EP3606542A4 (https=)
JP (2) JP7789303B2 (https=)
KR (2) KR20200003821A (https=)
CN (1) CN110769844B (https=)
AU (2) AU2018248324B2 (https=)
CA (1) CA3059354A1 (https=)
IL (1) IL269853A (https=)
MX (2) MX393998B (https=)
SG (1) SG11201909334TA (https=)
TW (1) TWI797116B (https=)
WO (1) WO2018187682A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251933B2 (en) * 2017-04-07 2019-04-09 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
US11666627B2 (en) 2017-04-07 2023-06-06 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
EP3773644A4 (en) * 2018-04-06 2021-06-02 Second Genome, Inc. PROTEINS FOR TREATMENT OF EPITHELIAL BARRIER FUNCTION DISORDERS
CN113347983A (zh) * 2018-10-09 2021-09-03 第二基因组股份有限公司 用于递送有效治疗上皮屏障功能障碍的蛋白质的乳酸乳球菌表达系统
US20210079086A1 (en) * 2019-08-21 2021-03-18 Astrazeneca Collaboration Ventures, Llc Use of Brazikumab to Treat Crohn's Disease
US11666629B2 (en) * 2020-01-10 2023-06-06 National Taipei University Of Technology Peptide interacting with toll-like receptor 2 and the composition comprising the same
CN113773364B (zh) * 2021-08-25 2023-04-28 无锡市儿童医院 小分子肽及其制备方法和应用
CN120882418A (zh) * 2022-11-04 2025-10-31 MiNK治疗公司 B细胞成熟抗原(bcma)嵌合抗原受体不变自然杀伤t细胞及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5571702A (en) 1991-03-29 1996-11-05 Genentech, Inc. Amplification method for detection of human PF4A receptors
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
DK3061766T3 (da) * 2009-04-28 2020-03-16 Univ Vanderbilt Sammensætninger og fremgangsmåder til behandlingen af sygdomme der involverer epitelcelleapoptose
GB201117313D0 (en) * 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
JP2014093482A (ja) 2012-11-06 2014-05-19 Toshiba Corp 固体撮像装置の製造方法および固体撮像装置
GB201306536D0 (en) * 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
WO2015014973A2 (en) * 2013-07-31 2015-02-05 Institut National De La Recherche Agronomique Use of specific glycoside phosphorylases for the implementation of phosphorolysis or reverse phosphorolysis reactions
WO2016203221A1 (en) * 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
US10251933B2 (en) 2017-04-07 2019-04-09 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
US11666627B2 (en) * 2017-04-07 2023-06-06 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders
US11174293B2 (en) 2017-06-02 2021-11-16 Second Genome, Inc. Proteins for the treatment of epithelial barrier function disorders

Also Published As

Publication number Publication date
KR102903277B1 (ko) 2025-12-23
US20240066095A1 (en) 2024-02-29
US20180289770A1 (en) 2018-10-11
MX393998B (es) 2025-03-24
US20200148728A1 (en) 2020-05-14
AU2023202844A1 (en) 2023-07-06
CN110769844B (zh) 2025-01-21
US11207376B2 (en) 2021-12-28
CA3059354A1 (en) 2018-10-11
TW201841649A (zh) 2018-12-01
KR20230144097A (ko) 2023-10-13
EP3606542A1 (en) 2020-02-12
MX2019012051A (es) 2020-02-12
TWI797116B (zh) 2023-04-01
JP7789303B2 (ja) 2025-12-22
US10251933B2 (en) 2019-04-09
JP2020516615A (ja) 2020-06-11
JP2024037834A (ja) 2024-03-19
AU2018248324A1 (en) 2019-10-31
WO2018187682A1 (en) 2018-10-11
AU2018248324B2 (en) 2023-02-09
CN110769844A (zh) 2020-02-07
KR20200003821A (ko) 2020-01-10
SG11201909334TA (en) 2019-11-28
MX2022008842A (es) 2022-08-02
EP3606542A4 (en) 2021-01-20

Similar Documents

Publication Publication Date Title
IL289650A (en) Azolopyrimidine for the treatment of cancer-related disorders
IL285151A (en) Methods of treating fgf21-associated disorders
IL275482A (en) Asketamine for the treatment of depression
GB2572126B (en) Pharmaceutical
GB2569961B (en) Pharmaceutical
GB2572125B (en) Pharmaceutical
IL269853A (en) Proteins for the treatment of epithelial barrier activity disorders
PL3618829T3 (pl) Pochodne chinazolinopirydyny do leczenia zaburzeń związanych z nowotworem
PL3634417T3 (pl) Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworem
EP3227330A4 (en) Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
EP3256218A4 (en) Kdm1a inhibitors for the treatment of disease
IL256077A (en) Fragments of mutated ras protein
IL259281B (en) History of bipyrazolyl used in the treatment of autoimmune diseases
IL270543A (en) Treatment methods for recurrent glioblastoma (RGBM)
PL3452075T3 (pl) Oftalmiczna kompozycja farmaceutyczna
EP3348273B8 (en) Compositions based on xyloglucan and proteins for the treatment of intestinal disorders
EP3256158A4 (en) Tolerance therapeutic for treating polypeptide induced allergy
PL3448340T3 (pl) Pomocniczy element aplikacyjny do opatrywania ran
ZA201902689B (en) Therapeutic protein
IL283273A (en) Pharmacy practices
ZA201901505B (en) Phenylalanine-free protein for the treatment of pku
MA54630A (fr) N,n-bis-2-mercaptoéthyle isophtalamide pour le traitment des maladies neurodégénératives
EP3507277B8 (en) Hydroxynorketamine derivatives for the treatment of disorders
HK40047137A (en) Proteins for the treatment of epithelial barrier function disorders
HK40025989A (en) Methods of treating neuropsychiatric disorders